763 related articles for article (PubMed ID: 25459643)
1. Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation.
Zilberberg J; Feinman R; Korngold R
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1000-7. PubMed ID: 25459643
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.
Anderson LD; Mori S; Mann S; Savary CA; Mullen CA
Cancer Res; 2000 Oct; 60(20):5797-802. PubMed ID: 11059776
[TBL] [Abstract][Full Text] [Related]
4. Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation.
Rezvani AR; Storb RF
J Autoimmun; 2008 May; 30(3):172-9. PubMed ID: 18242060
[TBL] [Abstract][Full Text] [Related]
5. Non-myeloablative transplants for malignant disease.
Storb RF; Champlin R; Riddell SR; Murata M; Bryant S; Warren EH
Hematology Am Soc Hematol Educ Program; 2001; ():375-91. PubMed ID: 11722994
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.
Tykodi SS; Warren EH; Thompson JA; Riddell SR; Childs RW; Otterud BE; Leppert MF; Storb R; Sandmaier BM
Clin Cancer Res; 2004 Dec; 10(23):7799-811. PubMed ID: 15585611
[TBL] [Abstract][Full Text] [Related]
7. siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(+) T cells in NOD/SCID/IL2Rg(null) mice.
van der Waart AB; Fredrix H; van der Voort R; Schaap N; Hobo W; Dolstra H
Cancer Immunol Immunother; 2015 May; 64(5):645-54. PubMed ID: 25724840
[TBL] [Abstract][Full Text] [Related]
8. HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study.
van Balen P; Jedema I; van Loenen MM; de Boer R; van Egmond HM; Hagedoorn RS; Hoogstaten C; Veld SAJ; Hageman L; van Liempt PAG; Zwaginga JJ; Meij P; Veelken H; Falkenburg JHF; Heemskerk MHM
Front Immunol; 2020; 11():1804. PubMed ID: 32973756
[TBL] [Abstract][Full Text] [Related]
9. Minor histocompatibility antigens as targets for immunotherapy using allogeneic immune reactions.
Akatsuka Y; Morishima Y; Kuzushima K; Kodera Y; Takahashi T
Cancer Sci; 2007 Aug; 98(8):1139-46. PubMed ID: 17521316
[TBL] [Abstract][Full Text] [Related]
10. The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond.
Tsirigotis P; Shimoni A; Nagler A
Ann Med; 2014 Sep; 46(6):384-96. PubMed ID: 24888385
[TBL] [Abstract][Full Text] [Related]
11. Minor histocompatibility antigens: allo target molecules for tumor-specific immunotherapy.
Goulmy E
Cancer J; 2004; 10(1):1-7. PubMed ID: 15000488
[TBL] [Abstract][Full Text] [Related]
12. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
[TBL] [Abstract][Full Text] [Related]
13. Targeting haematopoietic-specific minor histocompatibility antigens to distinguish graft-versus-tumour effects from graft-versus-host disease.
Spaapen R; Mutis T
Best Pract Res Clin Haematol; 2008 Sep; 21(3):543-57. PubMed ID: 18790454
[TBL] [Abstract][Full Text] [Related]
14. Minor histocompatibility antigens as targets of graft-versus-leukemia reactions.
Falkenburg JH; Marijt WA; Heemskerk MH; Willemze R
Curr Opin Hematol; 2002 Nov; 9(6):497-502. PubMed ID: 12394171
[TBL] [Abstract][Full Text] [Related]
15. CD4 Donor Lymphocyte Infusion Can Cause Conversion of Chimerism Without GVHD by Inducing Immune Responses Targeting Minor Histocompatibility Antigens in HLA Class II.
van Balen P; van Bergen CAM; van Luxemburg-Heijs SAP; de Klerk W; van Egmond EHM; Veld SAJ; Halkes CJM; Zwaginga JJ; Griffioen M; Jedema I; Falkenburg JHF
Front Immunol; 2018; 9():3016. PubMed ID: 30619360
[TBL] [Abstract][Full Text] [Related]
16. [Modification of Cytotoxic Lymphocytes with T Cell Receptor Specific for Minor Histocompatibility Antigen ACC-1Y].
Pilunov AM; Kuchmiy AA; Sheetikov SA; Filkin SY; Romaniuk DS; Rosov FN; Efimov GA
Mol Biol (Mosk); 2019; 53(3):456-466. PubMed ID: 31184611
[TBL] [Abstract][Full Text] [Related]
17. Cellular tumor vaccines administered after T cell-depleted allogeneic bone marrow transplantation induce effective anti-tumor immune responses.
Mundhada S; Shaw J; Mori S; Savary CA; Mullen CA
Leuk Lymphoma; 2005 Apr; 46(4):571-80. PubMed ID: 16019486
[TBL] [Abstract][Full Text] [Related]
18. Degree of predicted minor histocompatibility antigen mismatch correlates with poorer clinical outcomes in nonmyeloablative allogeneic hematopoietic cell transplantation.
Larsen ME; Kornblit B; Larsen MV; Masmas TN; Nielsen M; Thiim M; Garred P; Stryhn A; Lund O; Buus S; Vindelov L
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1370-81. PubMed ID: 20353833
[TBL] [Abstract][Full Text] [Related]
19. [Allogeneic hematopoietic stem-cell transplantation for hematological malignancies].
Michallet M; Dhedin N; Michallet AS
Bull Cancer; 2001 Sep; 88(9):908-26. PubMed ID: 11604365
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine.
Anderson LD; Petropoulos D; Everse LA; Mullen CA
Cancer Res; 1999 Apr; 59(7):1525-30. PubMed ID: 10197624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
